Molecular Signature in Focal Cortical Dysplasia: A Systematic Review of RNA and Protein Data
Jalleh Shakerzadeh1, Radim Jaroušek1,2, Zita Goliášová1
1Brno Epilepsy Centre, 1st Department of Neurology, St. Anne's University Hospital, Faculty of Medicine, Masaryk University, 602 00 Brno, Czech Republic.
Abstract:
Focal cortical dysplasia (FCD) is a major cause of drug-resistant epilepsy, yet its molecular basis remains poorly understood. Numerous studies have analyzed RNA, protein, and microRNA alterations, but results are often inconsistent across subtypes and methodologies. To address this gap, we conducted a systematic review integrating transcriptomic, proteomic, and microRNA data from 117 human studies of FCD subtypes I-III. Differentially expressed factors were extracted, categorized by subtype, and analyzed using pathway enrichment and network approaches. Our integrative analysis revealed convergent dysregulation of neuroinflammatory, synaptic, cytoskeletal, and metabolic pathways across FCD subtypes. Consistently altered genes, including IL1B, TLR4, BDNF, HMGCR, and ROCK2, together with dysregulated microRNAs such as hsa-miR-21-5p, hsa-miR-155-5p, and hsa-miR-132-3p, were linked to PI3K-Akt-mTOR, Toll-like receptor, and GABAergic signaling, emphasizing shared pathogenic mechanisms. Importantly, we identified overlapping transcript-protein patterns and subtype-specific molecular profiles that may refine diagnosis and inform therapeutic strategies. This review provides the first cross-omics molecular framework of FCD, demonstrating how convergent pathways unify heterogeneous findings and offering a roadmap for biomarker discovery and targeted interventions.
Insights
Focal cortical dysplasia (FCD), a cause of epilepsy, has unclear molecular roots. This review integrates multi-omics data, revealing shared pathway dysregulation across FCD subtypes and identifying potential biomarkers for diagnosis and therapy.
Area of Science:
- Neuroscience
- Genomics
- Molecular Biology
Background:
- Focal cortical dysplasia (FCD) is a leading cause of drug-resistant epilepsy.
- The underlying molecular mechanisms of FCD remain poorly understood, with inconsistent findings across studies.
Purpose of the Study:
- To systematically review and integrate transcriptomic, proteomic, and microRNA data from human FCD studies.
- To identify convergent molecular pathways and potential biomarkers across FCD subtypes I-III.
Main Methods:
- Systematic review of 117 human studies on FCD subtypes I-III.
- Integration of transcriptomic, proteomic, and microRNA data.
- Pathway enrichment and network analyses of differentially expressed factors.
Main Results:
- Convergent dysregulation of neuroinflammatory, synaptic, cytoskeletal, and metabolic pathways across FCD subtypes.
- Identification of consistently altered genes (e.g., IL1B, BDNF) and microRNAs (e.g., hsa-miR-21-5p).
- Linkage to key signaling pathways including PI3K-Akt-mTOR and Toll-like receptor signaling.
Conclusions:
- Established the first cross-omics molecular framework for FCD, unifying heterogeneous findings.
- Highlighted shared pathogenic mechanisms and identified subtype-specific molecular profiles.
- Provided a roadmap for FCD biomarker discovery and targeted therapeutic interventions.
Related Concept Videos
RNA Stability
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...


